Free Trial
NASDAQ:BCDA

BioCardia (BCDA) Stock Price, News & Analysis

BioCardia logo
$2.08 +0.08 (+4.00%)
Closing price 03:59 PM Eastern
Extended Trading
$2.09 +0.01 (+0.48%)
As of 04:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About BioCardia Stock (NASDAQ:BCDA)

Key Stats

Today's Range
$2.00
$2.08
50-Day Range
$1.82
$3.14
52-Week Range
$1.63
$4.66
Volume
26,555 shs
Average Volume
262,904 shs
Market Capitalization
$10.77 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$25.00
Consensus Rating
Strong Buy

Company Overview

BioCardia Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
76th Percentile Overall Score

BCDA MarketRank™: 

BioCardia scored higher than 76% of companies evaluated by MarketBeat, and ranked 276th out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    BioCardia has received a consensus rating of Strong Buy. The company's average rating score is 3.50, and is based on 1 buy rating, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    BioCardia has received no research coverage in the past 90 days.

  • Read more about BioCardia's stock forecast and price target.
  • Earnings Growth

    Earnings for BioCardia are expected to grow in the coming year, from ($3.52) to ($1.22) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of BioCardia is -0.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of BioCardia is -0.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    BioCardia has a P/B Ratio of 11.56. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about BioCardia's valuation and earnings.
  • Percentage of Shares Shorted

    0.35% of the float of BioCardia has been sold short.
  • Short Interest Ratio / Days to Cover

    BioCardia has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in BioCardia has recently decreased by 41.56%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    BioCardia does not currently pay a dividend.

  • Dividend Growth

    BioCardia does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.35% of the float of BioCardia has been sold short.
  • Short Interest Ratio / Days to Cover

    BioCardia has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in BioCardia has recently decreased by 41.56%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    BioCardia has a news sentiment score of 1.36. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.90 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 4 news articles for BioCardia this week, compared to 1 article on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, BioCardia insiders have bought more of their company's stock than they have sold. Specifically, they have bought $446,439.00 in company stock and sold $0.00 in company stock.

  • Percentage Held by Insiders

    20.00% of the stock of BioCardia is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 20.57% of the stock of BioCardia is held by institutions.

  • Read more about BioCardia's insider trading history.
Receive BCDA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BioCardia and its competitors with MarketBeat's FREE daily newsletter.

BCDA Stock News Headlines

Banks aren’t ready for this altcoin—are you?
In crypto, timing is everything. By the time the masses catch wind of this, the biggest gains could be ancient history. Are you ready to potentially change your financial future forever?
See More Headlines

BCDA Stock Analysis - Frequently Asked Questions

BioCardia's stock was trading at $2.18 at the start of the year. Since then, BCDA stock has decreased by 4.6% and is now trading at $2.08.
View the best growth stocks for 2025 here
.

BioCardia, Inc. (NASDAQ:BCDA) announced its quarterly earnings data on Wednesday, May, 14th. The company reported ($0.59) earnings per share for the quarter, missing the consensus estimate of ($0.39) by $0.20.
Read the conference call transcript
.

Shares of BioCardia reverse split on Thursday, May 30th 2024.The 1-15 reverse split was announced on Thursday, May 30th 2024. The number of shares owned by shareholders was adjusted after the market closes on Thursday, May 30th 2024. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

BioCardia (BCDA) raised $51 million in an initial public offering on the week of July 20th 2015. The company issued 3,900,000 shares at a price of $12.00-$14.00 per share. Cantor Fitzgerald & Co. served as the underwriter for the IPO and Roth Capital Partners and Maxim Group were co-managers.

Shares of BCDA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that BioCardia investors own include Invesco QQQ (QQQ), SPDR S&P 500 ETF Trust (SPY), SPDR Dow Jones Industrial Average ETF Trust (DIA), Predictive Oncology (POAI), Abbott Laboratories (ABT), Ford Motor (F) and Wells Fargo & Company (WFC).

Company Calendar

Last Earnings
5/14/2025
Today
7/02/2025
Next Earnings (Estimated)
8/12/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:BCDA
Employees
40
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$25.00
High Stock Price Target
$25.00
Low Stock Price Target
$25.00
Potential Upside/Downside
+1,099.6%
Consensus Rating
Strong Buy
Rating Score (0-4)
3.50
Research Coverage
2 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$7.95 million
Pretax Margin
-279,700.00%
Return on Equity
-30,792.60%

Debt

Sales & Book Value

Annual Sales
$60 thousand
Price / Cash Flow
N/A
Book Value
$0.18 per share
Price / Book
11.58

Miscellaneous

Free Float
4,142,000
Market Cap
$10.80 million
Optionable
Optionable
Beta
0.81
Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

This page (NASDAQ:BCDA) was last updated on 7/2/2025 by MarketBeat.com Staff
From Our Partners